Table 2 Characteristics between survivors and non-survivors
Variables | Survivors N = 42 | Non-survivors N = 17 | p value |
|---|---|---|---|
Age (months) | 17.5 (7.75–30.00) | 21.00 (10.00–52.50) | 0.344 |
Male, n (%) | 28 (66.7) | 12 (70.6) | 0.770 |
Weight (kg) | 10.00 (9.38–12.50) | 11.00 (9.00–17.50) | 0.400 |
Fever daysa | 9.50 (7.00–14.25) | 11.00 (8.00–15.50) | 0.563 |
Co-infection, n (%) | 13 (31.0) | 4 (23.5) | 0.408 |
Blood routine and infection indicators | |||
 Leukocyte,109/L | 5.55 (2.70–9.23) | 6.30 (2.60–11.50) | 0.960 |
 Hemoglobin,(g/L) | 92.26 ± 16.62 | 91.35 ± 19.63 | 0.857 |
 Neutrophil, 109/L | 3.91 (1.56–6.78) | 3.00 (1.11–10.15) | 0.867 |
 Platelets, 109/L | 195.50 (132.75–302.25) | 242.00 (67.50–356.00) | 0.947 |
 C reactive protein, mg/L | 37.40 (11.66–73.35) | 27.52 (9.44–55.00) | 0.808 |
Organ function indicators, n (%) | |||
 Alanine transaminase>50 U/L | 9 (21.4) | 7 (41.2) | 0.122 |
 Creatinin>62 umol/L | 0 (0.0) | 1 (5.9) | 0.288 |
 Creatine kinase isoenzyme>37 U/L | 13 (31.0) | 8 (47.1) | 0.242 |
 Prothrombin time>15 s | 6 (14.3) | 5 (29.4) | 0.162 |
 Activated partial prothrombin time>45 s | 18 (42.9) | 10 (58.8) | 0.266 |
 Fibrinogen<2 g/L | 9 (21.4) | 6 (35.3) | 0.216 |
Severity of Illness, n (%) | |||
 SOFA score ≥ 7 | 18 (42.9) | 15 (88.2) | 0.001 |
 OI ≥ 8 | 22 (52.4) | 13 (76.5) | 0.088 |
Treatment, n (%) | |||
 Human immunoglobulin | 38 (90.5) | 14 (82.4) | 0.320 |
 Glucocorticoid | 27 (64.3) | 8 (47.1) | 0.222 |
 Vasoactive drug | 23 (54.8) | 13 (76.5) | 0.122 |
 High titer NAbs plasma | 27 (64.3) | 6 (35.3) | 0.042 |
Adenovirus genotype, n (%) | |||
 ADV3 | 4 (9.5) | 1 (5.9) | 0.578 |
 ADV7 | 36 (85.7) | 16 (94.1) |  |
 Unkown | 2 (4.8) | 0 (0) |  |